Home - CEO Roadshow

SAN DIEGO, Aug. 11, 2011 (GLOBE NEWSWIRE) – Apricus Biosciences, Inc. (“Apricus Bio” or the “Company”) (Nasdaq:APRI) (http://www.apricusbio.com) announced today that Chairman, President and Chief Executive Officer, Dr. Bassam Damaj, was interviewed recently by the CEO Roadshow financial network (http://www.ceoroadshow/).

During the interview, Dr. Damaj reported on plans for the Company’s pipeline, including the proposed commercialization in Canada and Europeof Vitaros®, a topical treatment for erectile dysfunction.
Disclaimer

Interview with Mr. Frank Reynolds, Chairman and CEO of InVivo Therapeutics (NVIV.OB).

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a Cambridge, MA medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is affiliated with Massachusetts General Hospital in Boston. For more information on InVivo Therapeutics, please visit invivotherapeutics.com.
Disclaimer

Interview with Access Pharmaceuticals CEO, Mr. Jeff Davis discussing recent events at the company.

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

Disclaimer

Interview with Mr. George Naddaff, CEO of UFood Restaurant Group, Inc. (UFFC.OB).

About UFood Restaurant Group, Inc.

Headquartered in Boston, Food Restaurant Group, Inc. is a franchisor and operator of fast-casual food service restaurants. UFood Grill offers healthy lifestyle alternative to consumers in the fast-casual restaurant space and is positioned to become a leading player in the “better-for-you” quick-serve restaurant category. The Company is led by franchise innovator George Naddaff, who founded Boston Market and led the franchising of several companies including Sylvan Learning Center and Ranch*1. Mr. Naddaff has a veteran management team with a successful record in the franchise market. UFood is currently launching a growth plan to franchise nationwide. To learn more, visit ufoodgrill.com . Interested investors should email investor@ufoodgrill.com to be added to the UFood Restaurant Group email distribution list.

Further company information can be found at ufoodgrill.com.

Interested investors should email investor@ufoodgrill.com to be added to the UFood Restaurant Group email distribution list.
Disclaimer